{"gao_id": "GAO-10-201", "published": "2009-12-22T13:00:00Z", "released": "2010-01-11T08:00:00Z", "summary": "", "title": "Brand-Name Prescription Drug Pricing: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases", "topics": ["Generic drugs", "Drug pricing", "Manufacturing industry", "Prices and pricing", "Price increases", "Fair market value", "Substance abuse treatment", "Prescription drugs", "Competition", "Corporate mergers", "Cost control", "Pharmacological research", "Health Care", "Patents", "Cost analysis", "Research and development costs", "Therapy", "Pharmaceutical industry", "Price regulation"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-10-201", "versions": [{"title": "Highlights", "url": "https://www.gao.gov/assets/gao-10-201-highlights.pdf"}, {"title": "Full Report (40 pages)", "url": "https://www.gao.gov/assets/gao-10-201.pdf"}, {"title": "Accessible Text", "url": "https://www.gao.gov/assets/a299853.html"}]}